Nona’s expanding initiatives to fuel modality solutions, tech platform and more

Introduction

Nona Biosciences, a biotech entity along with its robust exclusive Harbour Mice® platform, is producing full-fledged human antibodies and has dug into AI-powered tools such as Hu-mAtrIx™. The company discover this AI tools in collaboration with pharma and academia to prepare for future biologics certainty for immunology, oncology and more.

The company has extended its potential into early clinical development. The services rendered by the company are based on screening, clearance and articulate IND-enabling studies. The company believes in strengthening its services via best-of-breed collaborations with giants like Pfizer and AstraZeneca.

Knock-Knock

Nona Biosciences is all set to mark its footprint in the drug development and discovery area. The company is extending the development framework and its unified discovery to contribute largely to the Investigator-Initiated Trials (IITs) and early clinical development. This smart strategy will give recognition and expansion to Nona’s potential beyond the same IND-enabling activities and discovery. This decision will bring differences as Nona will tighten the areas like toxicology, GMP manufacturing and CMC development.

The purpose behind this move is to bring light and help to the programs turning discovery into an early clinical development. The smartness of Nona merges exclusive antibody technology platforms and AI at the core of this expansion to help worldwide biopharmaceutical partners. The partners who are struggling to find an ideal roadway towards crucial development.

Idea

This brand new idea was clicked while Nona was regularly engaged in forming an efficient mechanism. To which the company hired Dr Di Hong as the Chief Executive Officer. His valuable leadership and experience centralised the aim on intensifying AI integration, enhance ecosystem related delivery model and leading platform development. By doing so, we will help the partners throughout their wide range of drug development processes.

Success Story

The company's tech strategy magnetised infinite numbers of global partners, and till now Nona has partnered with above 110 valuable partners and backed around 300 drug discovery programs along with 19+ molecules that modernised into a robust clinical establishment. The programs reached numerous therapeutic pathways that showed Nona's resilience, dedication and awareness regarding the need for drug development, while promoting the suitability of Nona’s platform portfolio.

Nona’s platform has gained the needed recognition and value on the huge international platform. Also, the Nona was nominated under the Best Startup category for the Prix Galien USA, 2025.